PLoS ONE · 2011 · 127 citations · 26 references
Public HealthInfectious DiseasesPharmacologyClinical PharmacologyHepatotoxicologyTuberculosis ControlDirectly Observed TherapyLiver DiseaseTuberculosis CareTuberculosis EpidemiologyTuberculosis PharmacotherapyTuberculosis PreventionAlanine Aminotransferase MonitoringDrug-induced Liver Injury AssessmentDrug-induced Liver Injury MonitoringLiver Toxicity AssessmentSerum Alanine AminotransferaseSerum Aminotransferase MonitoringTuberculosis Incidence EstimationTuberculosis Treatment Monitoring
BACKGROUND: Anti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the incidence of ATLI, to better understand its clinical features, and to evaluate its impact on anti-tuberculosis (TB) treatment in China. METHODOLOGY/PRINCIPAL FINDINGS: In a population-based prospective study, we monitored 4,304 TB patients receiving directly observed treatment strategy (DOTS) treatment, and found that 106 patients developed ATLI with a cumulative incidence of 2.55% (95% Confidence Interval [CI], 2.04%-3.06%). Nausea, vomiting and anorexia were the top three most frequently observed symptoms. There were 35 (33.02%) ATLI patients with no symptoms, including 8 with severe hepatotoxicity. Regarding the prognosis of ATLI, 84 cases (79.25%) recovered, 18 (16.98%) improved, 2 (1.89%) failed to respond to the treatment with continued elevation of serum alanine aminotransferase, and 2 (1.89%) died as result of ATLI. Of all the ATLI cases, 74 (69.81%) cases changed their anti-TB treatment, including 4 (3.77%) cases with medication administration change, 21 (19.81%) cases with drugs replacement, 54 (50.94%) cases with therapy interruption, and 12 (11.32%) cases who discontinued therapy. In terms of treatment outcomes, 53 (51.46%) cases had TB cured in time, 48 (46.60%) cases had therapy prolonged, and 2 (1.94%) cases died. Compared with non-ATLI patients, ATLI patients had a 9.25-fold (95%CI, 5.69-15.05) risk of unsuccessful anti-TB treatment outcomes and a 2.11-fold (95%CI, 1.23-3.60) risk of prolonged intensive treatment phase. CONCLUSIONS/SIGNIFICANCE: ATLI could considerably impact the outcomes of anti-TB treatment. Given the incidence of ATLI and the size of TB population in China, the negative impact is substantial. Therefore, more research and efforts are warranted in order to enhance the diagnosis and the prevention of ATLI.
26
Daphne Yee, Chantal Valiquette, Marthe Pelletier et al. · American Journal of Respiratory and Critical Care Medicine · 2003 · 841 citations
Cytochrome P450 2E1 Genotype and the Susceptibility to Antituberculosis Drug–Induced Hepatitis
Yi‐Shin Huang, Herng‐Der Chern, Wei‐Juin Su et al. · Hepatology · 2003 · 427 citations · Full text
Medicine, Pharmacology, Toxicology +15